Anxiety, Stress and Sleep Problems in People With Early Onset Dementia (Young-D)

September 23, 2022 updated by: Julie Vanderlinden, KU Leuven

The aim of this study is to

  • detect and assess needs of people with early onset dementia regarding anxiety, stress and sleep
  • implement a 6 week intervention pilot study in wich weekly (hourly) sessions are implemented in day care settings in order to decrease anxiety, stress and sleep problems in people with early onset dementia

Study Overview

Detailed Description

  1. needs detection by means of survey and interviews
  2. implementation of a 6 week program in day care facilities

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Flanders
      • Brussel, Flanders, Belgium, 1000
    • Oost-Vlaanderen
      • Gent, Oost-Vlaanderen, Belgium, 9000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • diagnosed with early onset dementia before age of 65Y

Exclusion Criteria:

  • severe dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group (pilot study)
  • needs detection by means of survey and interviews (mixed-methods)
  • 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises
  • needs detection by means of survey and interviews (mixed-methods)
  • 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
anxiety (GAD7 validated questionnaire)
Time Frame: 6 weeks
this is a subjective survey that measures the level of anxiety in daily life. It is a score of 7 items with a min of 0 and a max of 21. A higher score indicates a higher anxiety.
6 weeks
stress (perceived stress scale, PSS, validated questionnaire)
Time Frame: 6 weeks
this is a subjective survey that measures the level of stress in daily life. It is a score of 10 items with a min of 0 and a max of 40. A higher score indicates a higher stress level.
6 weeks
sleep (Insomnia severity index, ISI, validated questionnaire)
Time Frame: 6 weeks
this is a subjective survey that measures the level of insomnia. It is a score of 7 items with a min of 0 and a max of 28. A higher score indicates a worse level of insomnia
6 weeks
sleep (actigraph)
Time Frame: 6 weeks
this is an objective measurement that measures the sleep quantity
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
emotional well being (WEMWBS, Warwick emotional mental wellbeing scale)
Time Frame: 6 weeks
this is a subjective survey that measures the level of emotional well being in daily life. It is a score of14 items with a min of 0 and a max of 77. A higher score indicates a better wellbeing.
6 weeks
quality of life (QoL) (quality of life in dementia, QUALIDEM)
Time Frame: 6 weeks
this is a subjective survey that measures the level of QoL in daily life. It is a score of 40 items with a min of 0 and a max of 160. Per (7) subscales the scores are cumulated.
6 weeks
heart rate variance (HRV)
Time Frame: 6 weeks
this is an objective measurement that measures level of HRV in daily life, using (non-invasive photoplethysmography)
6 weeks
Depression (Patient Health Questionnaire PHQ-9, validated questionnaire)
Time Frame: 6 weeks
this is a subjective survey that measures the level of depression in daily life. It is a score of 10 items with a min of 0 and a max of 27. A higher score indicates a more severe level of depression
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Julie Vanderlinden, PhD, Odisee University of Applied Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2022

Primary Completion (Anticipated)

September 30, 2024

Study Completion (Anticipated)

September 30, 2025

Study Registration Dates

First Submitted

June 2, 2022

First Submitted That Met QC Criteria

September 23, 2022

First Posted (Actual)

September 26, 2022

Study Record Updates

Last Update Posted (Actual)

September 26, 2022

Last Update Submitted That Met QC Criteria

September 23, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on young-D program

Subscribe